KNSA · Kiniksa Pharmaceuticals, Ltd.

Kiniksa’s Q1 2026 results reflect strong commercial execution for ARCALYST, with $214.3 million in net product revenue — a 56% year-over-year increase — driven by broadening prescriber adoption (now >4,550 total prescribers) and increasing average therapy duration approaching three years, aligning with the natural history of recurrent pericarditis. Management explicitly attributes the raised full-year guidance ($930–$945 million, up from $900–$920 million) to momentum from both new and repeat prescribers, underscoring franchise scalability beyond launch-phase growth. Financially, net income more than doubled to $22.6 million despite a $60.5 million YoY increase in total operating expenses, largely attributable to $31.8 million higher collaboration expenses tied to ARCALYST profitability and $8.2 million higher R&D spend supporting KPL-387 clinical advancement. The company remains financially resilient: cash totaled $468.1 million at quarter-end with zero debt, and management reaffirmed expectation of annual cash flow positivity under its current operating plan. Pipeline progress is tightly coupled to commercial success — KPL-387’s Phase 2 dose-focusing data remains on track for H2 2026, and the Phase 3 pivotal trial is slated to initiate by year-end, positioning Kiniksa to potentially extend its leadership in IL-1 inhibition across multiple dosing paradigms. No non-GAAP adjustments or reconciliations were disclosed; all reported metrics are GAAP-based and presented without alternative measures.